Therefore, CD73 emerges as a novel target for the treatment of NSCLC with EGFR mutation and inhibiting CD73 to promote STING induction in tumor cells offers a new strategy for NSCLC treatment. The gene discussed is STING1; the disease is non-small cell lung carcinoma.